ArticleJournal of clinical microbiology2006
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 1 synthesis or guideline pooled it, 359 citations in OpenAlex.
- Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.PloS one · 2012Pooled it
- Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.International journal of hematology · 2016Trial
- A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections.BMC infectious diseases · 2012Trial
- Defining risk factors for red man syndrome in children and adults.The Pediatric infectious disease journal · 2012Trial
- Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.Antimicrobial agents and chemotherapy · 2011Trial
- Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?The Pediatric infectious disease journal · 2010Trial
- The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.International journal of clinical practice · 2009Trial
- Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.The Journal of antimicrobial chemotherapy · 2008Trial
- Suppression of Quorum Sensing and Virulence Factors by Meloxicam and Celecoxib in Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Vancomycin MIC creep and the emergence of oxacillin-susceptible MRSA: A three-year surveillance study from a tertiary care centre.New microbes and new infections · 2026Article
- Bi-Layered Tablets as a Novel Platform for Wound Healing and Synergistic Combination Therapy.AAPS PharmSciTech · 2026Article
- Z‑Amino Acids Present Innovative Antimicrobial and Antibiofilm Properties against Methicillin-Susceptible and -ResistantACS omega · 2026Article
- Balanced enhancement of antibacterial activity and biocompatibility in chitosan-vancomycin 3D-printed scaffolds through mesoporous bioactive glass addition.Journal of drug delivery science and technology · 2025Article
- Distinguishing methicillin-resistant Staphylococcus aureus from methicillin-sensitive strains by combining FeMikrochimica acta · 2024Article
- Epidemiology ofAntibiotics (Basel, Switzerland) · 2023Review
- Article
- Phenotypic detection of methicillin resistance, biofilm production, and inducible clindamycin resistance in Staphylococcus aureus clinical isolates in Kathmandu, Nepal.Tropical medicine and health · 2022Article
- Transcriptomics and systems biology identify non-antibiotic drugs for the treatment of ocular bacterial infection.iScience · 2022Article
- Elasnin Effectively Eradicates Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus Biofilms.Microbiology spectrum · 2022Article
- In vitro investigations of Staphylococcus aureus biofilms in physiological fluids suggest that current antibiotic delivery systems may be limited.European cells & materials · 2022Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is one of the most commonly isolated organisms in nosocomial infections. While the prevalence of methicillin-resistant S. aureus (MRSA) continues to increase worldwide, there is concern about an increase in vancomycin MICs among S. aureus strains. The prevalence of MRSA and vancomycin MIC trends in S. aureus from patients in a university hospital were analyzed. Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) reference broth microdilution MIC testing was performed on all clinically relevant S. aureus isolates from January 2000 through December 2004. A total of 6,003 S. aureus isolates were analyzed. No vancomycin-resistant S. aureus isolates were detected. One MRSA isolate had a vancomycin MIC of 8 mug/ml and was confirmed as vancomycin-intermediate S. aureus. Among the 6,002 remaining isolates, a shift in vancomycin MICs from </=0.5 to 1.0 mug/ml was observed during the 5-year period. The percentage of S. aureus isolates with a vancomycin MIC of 1 mug/ml in 2004 was significantly higher than the percentage of isolates in 2000 (70.4% versus 19.9%; P < 0.01). This vancomycin MIC shift was more notable in methicillin-susceptible S. aureus. Our 5 years of routine testing of clinical isolates using the CLSI reference broth microdilution MIC method demonstrated a tendency toward decreasing susceptibility to vancomycin in S. aureus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.